6/810
VC3
9-3-02

PATENT
0459-0461P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: WEIDNER, Morten Conf.: 9245

Appl. No.: 09/613,468 Group: 1616

Filed: July 10, 2000 Examiner: GOLLAMUDI, S.

For: NOVEL COMPOSITION CONTAINING EXTRACTS OF BUTYROSPERMUM PARKII AND THE USE OF SUCH A COMPOSITION FOR PREPARING A MEDICAMENT OR A DIETARY SUPPLEMENT FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY HYPERSENSITIVITY OR PAIN

SMALL ENTITY TRANSMITTAL FORM

Assistant Commissioner for Patents
Washington, DC 20231

August 12, 2002

Sir:

Transmitted herewith is an amendment in the above-identified application.

☒ Applicant claims small entity status under 37 C.F.R. § 1.27.

☒ The enclosed document is being transmitted via the Certificate of Mailing provisions of 37 C.F.R. § 1.8.

☐ The enclosed document is being transmitted via facsimile.

The fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	37	-	29	=	8	$ 9	$72.00
INDEPENDENT	2	-	3	=	0	$ 42	$0.00
_____ FIRST PRESENTATION OF A MULTIPLE CLAIM						$140	$0.00
						TOTAL	$72.00

PATENT
Attorney Docket No. 0459-0461P

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: WEIDNER, M. CONF: 9245

SERIAL NO.: 09/613,468 GROUP: 1616

FILED: July 10, 2000 EXAMINER: GOLLAMUDI, S.

FOR: NOVEL COMPOSITION CONTAINING EXTRACTS OF BUTYROSPERMUM PARKII AND THE USE OF SUCH A COMPOSITION FOR PREPARING A MEDICAMENT OR A DIETARY SUPPLEMENT FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY HYPERSENSITIVITY OR PAIN

RESPONSE TO OFFICE ACTION

Assistant Commissioner for Patents
Washington, D.C. 20231

August 12, 2002

Sir:

In response to the Examiner's Office Action dated February 12, 2002, the period for response having been extended three (3) months to August 12, 2002, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

AMENDMENTS

Please amend the claims as follows:

C1

1 (Amended). A pharmaceutical composition or a dietary supplement comprising an extract or concentrate of Butyrospermum parkii comprising at least 5% (w/w) of a Butyrospermum-triterpene

fraction such that said composition comprises at least 5 % w/w of said Butyrospermum-triterpene fraction,

said Butyrospermum-triterpene fraction comprising:
- at least 2% (w/w) lupeol;
- at least 2% (w/w) α-amyrin and/or β-amyrin; and
- at least 2% (w/w) butyrospermol;

wherein said triterpenes may be in the form of free alcohols or esters thereof.

2. (Amended) The pharmaceutical composition or a dietary supplement according to claim 1, wherein said Butyrospermum-triterpene fraction comprises:
- 10-40% (w/w) lupeol;
- 10-40% (w/w) α-amyrin and/or β-amyrin;
- 10-40% (w/w) butyrospermol.

3. (Amended) The pharmaceutical composition or dietary supplement according to claim 1, wherein the extract or concentrate of Butyrospermum parkii further comprises a sterol fraction comprising at least one sterol selected from the group consisting of stigmasterol, avanasterol, 24-methyl-cholest-7-enol, karitesterol A, karitesterol B and α-spinasterol, wherein said sterols may be in the form of free alcohols or esters thereof.

4 (Amended). The pharmaceutical composition or dietary supplement according to claim 1, wherein the Butyrospermum-triterpene fraction comprises up to 100% (w/w) of the extract or concentrate of Butyrospermum parkii.

5. (Amended) The pharmaceutical composition or dietary supplement according to claim 3, wherein the ratio between the Butyrospermum-triterpene fraction and the sterol fraction is in the range of 1:100 to 500:1 (w/w).

6. (Amended) The pharmaceutical composition or dietary supplement according to claim 1, further comprising an extract of Calendula officinalis.

7. (Amended) The pharmaceutical composition according to claim 1 formulated for systemic administration.

8. (Amended) The pharmaceutical composition according to claim 1 formulated for topical administration.